Abstract
A major population of cancer patients experience anaemia during the course of their disease process and by treatments such as chemotherapy, radiotherapy and also whilst on supportive therapies (Groopman and Itri 1999). Red Blood Transfusion (RBT) is the most commonly used form of correction of anaemia worldwide and in the United Kingdom (U.K) alone over 3 million blood product transfusions are carried out each year (McClelland et al. 2007).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amato A, Pescatori M (2006) Peri-operative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 25(1): CD005033
Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82(1): 93–7
Bokemeyer C, Aapro MS, Courdi A, Foubertd H., Linke A, Osterborg L, Repetto, Soubeyran P (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update in anaemic patients with cancer. Eur J Cancer 43: 258–270
Booth S, Bruera E (2003) Palliative care consultations in haemato-oncology. Oxford University Press, Oxford
Daly T, Poulsen MG, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q (2003) The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol 68(2): 113–122
Engert A (2000) Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Disease Management and Health Outcomes 8: 259–272.
Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H (1998) Anemia is associated with decreased survival and increased loco-regional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85–27. Int J Radiat Oncol Biol Phys 1;42(5): 1069–1075
Gleeson C, Spencer D (1995) Blood transfusion and its benefits in palliative care. Palliat Med 9(4): 307–313
Grant DG, Hussain A, Hurman D (1999) Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 113(9): 829–833
Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 15; 86(8): 1528–1536
Groopman JE, Itri LM (1999) Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634.
Leibovitz A, Baumoehl Y, Walach N, Kaplun V, Sigler E, Balan S, Habot B (2004) Medical staff attitudes: views and positions regarding blood transfusion to terminally ill cancer patients. Am J Clin Oncol 27(5): 542–546
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15): 2293–2306
MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining haemoglobin during chemo-radiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64(1): 37–40
McClelland DBL, et al (2007) Handbook of transfusion medicine, 4th edn. TSO publishers, www.tsoshop.co.uk
Monti M, Castellani L, Berlusconi A, Cunietti E (1996) Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain and Symptom Management 12(1): 18–22
Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, Dolan S, Plante RK, Lau CY, Chang J (2006) Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. Oncologist 11(1): 73–82
Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20(19): 4083–4107
Twycross R, Wilcock A (Editors in Chief) (2007) Palliative care formulary, 3rd edn. Palliativedrugs.com Ltd, Nottingham, UK
Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DBL, Skacel P, Barbara JAJ (1999) Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. Br Med J 319: 16–19
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag/Wien
About this chapter
Cite this chapter
Jacob, J.K., Barrett-Lee, P.J. (2008). When to use red blood cell transfusions in cancer patients with solid tumours?. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-211-69459-6_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-25223-9
Online ISBN: 978-3-211-69459-6
eBook Packages: MedicineMedicine (R0)